{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Leichman L"],"funding":["NCI NIH HHS"],"pagination":["172-7"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4746089"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["21(2)"],"pubmed_abstract":["<h4>Background</h4>Effective new agents for patients with colorectal cancer (CRC) with disease progression during standard therapy regimens are needed. We hypothesized that poly ADP ribose polymerase (PARP) inhibitor therapy in patients with CRC and inefficient tumor DNA repair mechanisms, such as those with high-level microsatellite instability (MSI-H), would result in synthetic lethality.<h4>Methods</h4>This was an open-label phase II trial testing olaparib 400 mg p.o. b.i.d. for patients with disseminated, measurable CRC failing standard therapies with centrally confirmed tumor MSI status. The primary endpoint was the tumor response, assessed by RECIST, version 1.0. The secondary endpoints were safety/toxicity, progression-free survival (PFS), and overall survival (OS).<h4>Results</h4>T"],"journal":["The oncologist"],"pubmed_title":["Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer."],"pmcid":["PMC4746089"],"funding_grant_id":["P30 CA006927"],"pubmed_authors":["Berlin J","Lenz HJ","Hamilton SR","Leichman L","Gold P","Leichman CG","Cason RC","Chan E","Hochster HS","Cohen SJ","Groshen S","Locker G","O'Neil BH","Fielding A","Messersmith W","Cohen D","Boman B"],"additional_accession":[]},"is_claimable":false,"name":"Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer.","description":"<h4>Background</h4>Effective new agents for patients with colorectal cancer (CRC) with disease progression during standard therapy regimens are needed. We hypothesized that poly ADP ribose polymerase (PARP) inhibitor therapy in patients with CRC and inefficient tumor DNA repair mechanisms, such as those with high-level microsatellite instability (MSI-H), would result in synthetic lethality.<h4>Methods</h4>This was an open-label phase II trial testing olaparib 400 mg p.o. b.i.d. for patients with disseminated, measurable CRC failing standard therapies with centrally confirmed tumor MSI status. The primary endpoint was the tumor response, assessed by RECIST, version 1.0. The secondary endpoints were safety/toxicity, progression-free survival (PFS), and overall survival (OS).<h4>Results</h4>T","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 Feb","modification":"2025-04-21T22:19:08.402Z","creation":"2019-03-27T02:08:41Z"},"accession":"S-EPMC4746089","cross_references":{"pubmed":["26786262"],"doi":["10.1634/theoncologist.2015-0319"]}}